To evaluate the efficacy and safety of renizgamglogene autogedtemcel (reni-cel) in increasing fetal hemoglobin levels in patients with severe sickle cell disease.
Key Findings:
Total hemoglobin increased from 9.8 g/dL to 13.8 g/dL by six months.
Fetal hemoglobin levels rose from 2.5% to 48.1%.
27 out of 28 patients experienced no severe vaso-occlusive events post-infusion.
F-cell levels exceeded 99% by month 6.
Neutrophil recovery median was 23 days and platelet recovery was 25 days.
Interpretation:
The CRISPR/Cas12a gene-editing technology shows potential for a functional cure in sickle cell disease, with significant increases in fetal hemoglobin and reduced vaso-occlusive events.
Limitations:
The RUBY trial was terminated early, limiting the scope of findings.
Safety findings were consistent with existing treatments but require further validation.
Conclusion:
These results support promoter editing as a promising strategy for fetal hemoglobin reactivation in sickle cell disease, potentially offering a new treatment avenue.
